SS-31

SS-31 Peptide: Complete Guide to Mitochondrial Membrane Protection

Its proposed ability to improve mitochondrial efficiency and reduce reactive oxygen species production has positioned it as an important compound in studies focused on metabolic resilience, tissue protection, and mitochondrial disease.

What Is SS-31?

Elamipretide, commonly referred to as SS-31, is a synthetic tetrapeptide developed to target mitochondrial dysfunction at the membrane level. The compound, with the amino acid sequence D-Arg-Dmt-Lys-Phe-NH2, was originally designed by mitochondrial researcher Hazel H. Szeto at Weill Cornell Medicine. Instead of broadly circulating throughout tissues, SS-31 selectively targets and localizes to the inner mitochondrial membrane through its affinity for cardiolipin. Interest in the SS-31 peptide has grown because mitochondrial dysfunction is increasingly recognized as a major contributor to aging, cardiovascular disease, neurodegeneration, and metabolic decline. By directly interacting with cardiolipin, a phospholipid unique to the inner mitochondrial membrane, SS-31 has been studied for its ability to stabilize mitochondrial architecture and improve energy production efficiency. The compound has been evaluated in Phase 2 clinical studies in heart failure and has more recently been studied in rare mitochondrial diseases. In 2025, the FDA granted accelerated approval to elamipretide under the brand name Forzinity for the treatment of Barth syndrome in patients weighing at least 30 kg.

• Barth syndrome is a rare X-linked genetic disorder caused by mutations in the TAZ gene that affect cardiolipin metabolism, which is mechanistically aligned with elamipretide's primary mode of action. This represents elamipretide's first approved therapeutic indication in any jurisdiction.

Researchers continue to evaluate the compound for applications involving mitochondrial restoration, ischemia-reperfusion injury, and age-associated decline in cellular bioenergetics. SS-31 is part of a broader class of mitochondria-targeted research compounds classified within the peptides category.

SS-31 Mechanism of Action

SS-31 functions differently from standard antioxidant compounds because it specifically targets cardiolipin within mitochondria. Cardiolipin plays a critical structural role in maintaining the integrity of the electron transport chain and supporting ATP synthesis. Cardiolipin damage contributes to impaired oxidative phosphorylation, increased reactive oxygen species production, and apoptosis. At the mitochondrial level, SS-31 binds to cardiolipin and helps stabilize the inner mitochondrial membrane. This interaction supports the function of electron transport chain complexes I–IV, improving electron flow efficiency while reducing electron leakage, which generates oxidative stress. One of the major proposed mechanisms involves reducing mitochondrial ROS production. Excessive ROS generation contributes to lipid peroxidation, mitochondrial DNA damage, and inflammatory signaling. By limiting oxidative injury at the membrane level, SS-31 may preserve mitochondrial performance under stress conditions such as ischemia or aging. The peptide has also demonstrated anti-apoptotic properties in preclinical studies. Stabilization of cardiolipin may help prevent cytochrome c release from mitochondria, reducing activation of programmed cell death pathways. Researchers explore this mechanism in cardiac, renal, and neurological injury models. Another important area of investigation involves mitochondrial cristae morphology. Cristae are the folded membrane structures responsible for efficient ATP production. Age-related or disease-associated mitochondrial dysfunction often causes disorganization of cristae. Experimental studies suggest SS-31 may help restore more organized cristae architecture, potentially improving mitochondrial energy efficiency across tissue types.

SS-31 Benefits

SS-31 has been studied in mitochondrial and cellular health research due to its proposed roles in membrane stabilization and in reducing oxidative stress. The following summarizes key areas of investigation. Unless otherwise noted, applications beyond Barth syndrome remain investigational and have not been established as clinical indications.

Mitochondrial Function Restoration

One of the primary research interests surrounding SS-31 is its ability to restore mitochondrial function in aging tissues. Declining mitochondrial efficiency contributes to fatigue, impaired recovery, and reduced cellular resilience. Experimental data suggest that SS-31 may improve ATP generation and decrease oxidative stress markers in aged cells, though these findings are primarily preclinical. Several preclinical investigations have demonstrated improved mitochondrial respiration following SS-31 administration. This restoration of oxidative phosphorylation efficiency has positioned the peptide as a candidate for broader research into longevity and healthy aging. Researchers evaluating NAD-based approaches to mitochondrial metabolism may find complementary context in the NAD guide, which covers sirtuin activation and energy substrate pathways.

Cardioprotective Effects

Cardiovascular applications remain among the most studied areas of SS-31 research. The heart relies heavily on mitochondrial ATP production, making mitochondrial dysfunction particularly relevant in heart failure and ischemic disease. In animal models, SS-31 has been associated with improvements in left ventricular function and enhanced cardiac energetics. Human clinical research, including the RESTORE trial, evaluated intravenous elamipretide in patients with heart failure with reduced ejection fraction. Research reported signals of improvement in left ventricular end-systolic volume following SS-31 administration in some patient cohorts. However, major trials in heart failure have not consistently met primary endpoints, and the compound's role in this indication remains under active investigation rather than established.

Renal Protection

Elamipretide (Forzinity) received FDA accelerated approval in 2025 for Barth syndrome in patients weighing at least 30 kg. Barth syndrome is caused by dysfunction of cardiolipin remodeling due to mutations in the TAZ gene, which directly impairs mitochondrial membrane structure. The mechanistic alignment between elamipretide's cardiolipin-targeting activity and the underlying pathology of Barth syndrome provided the scientific rationale for this development program.

Renal Protection

Kidney tissue is highly dependent on mitochondrial energy production, especially during ischemic stress. SS-31 has been studied in ischemia-reperfusion injury models involving renal tissue, with preclinical data suggesting the peptide may reduce tubular injury, oxidative damage, and inflammatory signaling following ischemic events. Note: These findings are preclinical and have not been validated in large human trials.

Neuroprotective Research

Neurons are particularly vulnerable to mitochondrial dysfunction because of their high energy demands. SS-31 has been investigated in several neurodegenerative disease models, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Findings remain early-stage and preclinical; clinical applications in neurodegeneration have not been established.

Anti-Aging Applications

Researchers studying longevity interventions have explored SS-31 as part of broader mitochondrial restoration protocols. Rather than functioning as a traditional stimulant or metabolic enhancer, SS-31 is primarily viewed as a structural mitochondrial support peptide. Preclinical studies involving aged animals have demonstrated improvements in muscle endurance, mitochondrial efficiency, and tissue bioenergetics following administration. Human longevity data are lacking; anti-aging applications remain speculative at this stage. Because mitochondrial decline affects multiple organ systems, SS-31 has gained attention in integrative longevity research. MOTS-C, studied for its metabolic regulatory and AMPK-activating properties, is sometimes explored alongside SS-31 in such protocols. The MOTS-C guide outlines its distinct mechanism and research context.

SS-31 Dosage & Administration

Current dosing information for the SS-31 peptide is derived entirely from clinical trials and preclinical investigations. There is no universally established dosing standard; protocols have varied significantly by indication, patient population, and study design, and the following should be interpreted accordingly. Clinical heart failure studies have evaluated intravenous administration. In the RESTORE trial, investigators used a 0.05 mg/kg IV infusion delivered over approximately four hours. Other trials have used different doses, routes, and schedules depending on the specific disease context. Subcutaneous administration is discussed in longevity and outpatient research settings. Dosing parameters in these contexts are not standardized and should not be extrapolated from the clinical trial data above. Researchers evaluating SS-31 frequently monitor cardiovascular function, exercise tolerance, fatigue markers, mitochondrial bioenergetic parameters, renal biomarkers, and oxidative stress indicators. Because mitochondrial-targeted therapies remain largely investigational outside of Barth syndrome, dosing strategies continue to evolve as clinical evidence emerges.

SS-31 Protocol

Research protocols involving SS-31 focus on mitochondrial optimization, cellular resilience, and oxidative stress management. All protocols below describe investigational research contexts only.

Longevity-Oriented Protocols

In investigational longevity stacks, SS-31 is generally viewed as the membrane-protective component, while NAD-focused compounds address cellular energy metabolism and sirtuin activity, and Epithalon is explored for its telomere-related and neuroendocrine signaling properties. The Epithalon guide covers its distinct mechanism and preclinical longevity data.

Cardiac Protection Research

Cardiac-focused protocols have evaluated SS-31 as a standalone peptide because of its direct interactions with cardiolipin in cardiac tissue. Its approved indication in Barth syndrome represents the most clinically advanced application. In heart failure research, its role remains investigational following mixed results across trials.

Exercise Performance Applications

Experimental protocols have explored SS-31 administration in contexts involving intense training or metabolic stress, with the proposed rationale involving improved ATP production efficiency and reduced oxidative stress accumulation. These applications are speculative and have not been validated in human performance studies.

SS-31 Side Effects

Available clinical data suggest SS-31 is generally well tolerated. Most reported adverse events in human studies have been mild and transient, including injection site irritation, mild redness or swelling, and temporary nausea at higher doses. Clinical trials have not identified significant systemic toxicity, and intravenous studies in cardiovascular populations have also reported relatively favorable safety findings. Long-term safety data remain limited as the compound continues through clinical development across multiple indications.

SS-31 vs NAD vs MOTS-C vs Epithalon

Compound	Primary Mechanism	Target Tissue	Administration	Clinical Data Level
SS-31	Cardiolipin stabilization and mitochondrial membrane protection	Heart, skeletal muscle, kidney, neurons	SC or IV	FDA accelerated approval (Barth syndrome, 2025); mixed Phase 2 data in heart failure; other uses investigational
NAD	Supports mitochondrial energy metabolism and sirtuin signaling	Systemic cellular metabolism	IV, SC, oral precursors	Extensive metabolic research; no approved indication
MOTS-C	Metabolic regulation and insulin sensitivity signaling	Skeletal muscle and metabolic tissues	SC	Early clinical and preclinical data
Epithalon	Telomere and pineal signaling research	Neuroendocrine and aging pathways	SC	Primarily preclinical and longevity-focused

SS-31 differs from NAD-centered therapies because it primarily targets mitochondrial membrane integrity rather than intracellular metabolic cofactor availability. Compared with MOTS-C, SS-31 has a more protective and structural role. Many researchers view these compounds as complementary because they influence different aspects of mitochondrial biology.

FAQs — SS-31

1. What does SS-31 stand for?

SS-31 is a research compound designation rather than a commonly expanded acronym in official clinical usage. The compound is also known as Elamipretide, MTP-131, and Bendavia across different research publications and development programs. It was developed specifically to target mitochondrial dysfunction by interacting with cardiolipin on the inner mitochondrial membrane.

2. Is SS-31 the same as Elamipretide?

Yes. SS-31, Elamipretide, MTP-131, and Bendavia all refer to the same mitochondrial-targeted tetrapeptide compound. Different names reflect different stages of development and research contexts. The compound's most recent approved name is Forzinity, under which it received FDA accelerated approval in 2025 for Barth syndrome.

3. Does SS-31 improve heart function?

Phase 2 clinical research, including the RESTORE trial (Daubert et al., Circ Heart Fail, 2017) reported some signals of improvement in left ventricular end-systolic volume in heart failure patients, but major trials have not consistently met primary endpoints. In Barth syndrome, a cardiolipin metabolism disorder, elamipretide received FDA accelerated approval in 2025 (Forzinity), representing its most clinically established application to date.

4. Can SS-31 slow aging?

Mitochondrial dysfunction is considered a central mechanism of biological aging, affecting energy production, cellular repair, and tissue resilience. Because SS-31 helps stabilize mitochondrial membranes and improve bioenergetic efficiency, researchers view it as a candidate in longevity investigations. However, human longevity data are absent, and anti-aging applications remain speculative and entirely investigational at this stage.

References

1. Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017;10(12):e004389. doi:10.1161/CIRCHEARTFAILURE.117.004389
2. Zhu Y, Luo M, Bai X, et al. SS-31, a mitochondria-targeting peptide, ameliorates kidney disease. Oxid Med Cell Longev. 2022;2022:1295509. doi:10.1155/2022/1295509
3. Du X, Zeng Q, Luo Y, et al. Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction. 2024;75:101846. doi:10.1016/j.mito.2024.101846
4. Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478. doi:10.1038/s41436-020-01006-8